LexDanaLexDanabeta
Inventor

Andrew Lees

Inventor
Silver Spring, MD, US

Overview

34→
Patents
1996–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 34 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary
A61KPreparations for medical, dental or toiletry purposes25%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations19%
C07KPeptides14%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests8%
Y02ATechnologies for adaptation to climate change6%
C12NMicroorganisms or enzymes5%
C08BPolysaccharides4%
C07DHeterocyclic compounds4%
C08HDerivatives of natural macromolecular compounds4%
G06FElectric digital data processing4%
PatentTitleYear
11,119,902Creating a higher order mutant for mutation testing software202111,113,229Providing a continuation point for a user to recommence consuming content202111,060,123Production of soluble recombinant protein without n-terminal methionine202110,597,664Expression and purification of CRM proteins and related proteins, and protein domains202010,296,349Allocating a register to an instruction using register index information201910,093,704Expression and purification of CRM197 and related proteins201810,095,518Allowing deletion of a dispatched instruction from an instruction queue when sufficient processor resources are predicted for that instruction20189,259,480'Activation of polysaccharides via the cyanylating agent, 1-cyanobenzotriazole (1-CBT), in the preparation of polysaccharide/protein conjugate vaccines'20169,254,337'Activation of polysaccharides via the cyanylating agent, 2-cyanopyridazine-3(2H)-one (2-CPO), in the preparation of polysaccharide/protein conjugate vaccines'20169,248,197'Activation of polysaccharides via the cyanylating agent, 1-cyanoimidazole (1-Cl), in the preparation of polysaccharide/protein conjugate vaccines'20169,044,517'Activation of polysaccharides via the cyanylating agent, 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), in the preparation of polysaccharide/protein conjugate vaccines'20158,647,621'Method of producing protein-carbohydrate vaccines reduced in free carbohydrate'20148,383,783'Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels'20137,777,017'Nucleic acids encoding opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria'20107,566,540'Monoclonal antibody which agglutinates E. coli having the CS4-CFA/I family protein'20097,470,441'Method for preparing Mucuna pruriens seed extract'20087,452,533'Antimicrobial polymer conjugate containing lysostaphin and polyethylene glycol'20087,250,494'Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria'20077,166,708'Process for preparing conjugate vaccines and the conjugate vaccines'20077,101,562'Conjugate vaccines for the prevention of dental caries'20067,094,883'Monoclonal antibody which agglutinates E. coli having the CS4-CFA/I family protein'20066,756,041'Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process'20046,585,973'Method for preparing solid phase conjugated vaccine'20036,432,679'Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220'20026,309,646'Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates'20016,299,881'Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts'20016,284,250'Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media'20016,248,334'Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process'20016,087,328'Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines'20005,955,079'Dual carrier immunogenic construct'19995,849,301'Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents'19985,693,326'Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents'19975,651,971'Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents'19975,585,100'Dual carrier immunogenic construct'1996

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1996–2006Patents assigned to JACKSON H M FOUND MILITARY MED (14)· patent assignee history
1996–1999Based in Baltimore, MD, US· patent location history
1997–2021Based in Silver Spring, MD, US· patent location history
2007–2010Patents assigned to BIOSYNEXUS INC (4)· patent assignee history
2008Based in London, GB· patent location history
2013–2021Patents assigned to FINA BIOSOLUTIONS LLC (9)· patent assignee history
2013–2015Patents assigned to LEES ANDREW (3)· patent assignee history
2018–2019Patents assigned to ADVANCED RISC MACH LTD (2)· patent assignee history
2018–2019Based in Cambridge, GB· patent location history
2021Based in Ferndown, GB· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
JACKSON H M FOUND MILITARY MED141996–2006
FINA BIOSOLUTIONS LLC92013–2021
BIOSYNEXUS INC42007–2010
LEES ANDREWself32013–2015
ADVANCED RISC MACH LTD22018–2019
Locations
LocationPatentsSpan
Silver Spring, Maryland, US271997–2021
Ferndown, GB22021
Cambridge, GB22018–2019
Baltimore, Maryland, US21996–1999
London, GB12008